A Study to Evaluate the Safety and Effectiveness of Hypofractionation Proton Beam Therapy in Patients with Clinically Localized, Intermediate, or High Risk Prostate Cancer

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and effectiveness of a moderate hypofractionation regimen of proton beam therapy with same time treatment of the prostate, seminal vesicles, and the regional pelvic nodes  for patients who have clinically localized, high risk or unfavorable intermediate risk prostate cancer.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Males
  • Age ≥ 18 years
  • Histological confirmation of adenocarcinoma of the prostate within 6 months of study enrollment
    • Clinical stage T1-2 N0 M0, Gleason Score 7, Prostate Specific Antigen (PSA) 20-100 ng/mL
    • Clinical stage any T N0 M0, Gleason Score 8-10, PSA ≤ 100 ng/mL
    • Clinical stage T3-4 N0 M0, any Gleason Score, PSA ≤ 100 ng/mL
    • Clinical stage T1-2 N0 M0, Gleason Score 4+3, PSA 10-20 ng/mL
  • Zubrod performance score (PS) ≤ 1
  • Total bilirubin, aspartate aminotransferase, alkaline phosphatase, and serum creatinine: < 2 x upper normal limit
  • Signed informed consent

Exclusion Criteria

  • Any known nodal (N1) or distant metastasis (M1)
  • Previous androgen deprivation therapy lasting more than 6 months
  • History of inflammatory bowel disease
  • Presence of a hip prosthesis
  • Prior pelvic radiotherapy or prostatectomy
  • Prior or concurrent antineoplastic agents (chemotherapy)
  • Previous or concurrent malignancy other than non-melanoma skin cancer within 5 years of diagnosis of prostate cancer
  • Inability to start the protocol treatment within 1 month after study enrollment
  • Medical or psychiatric conditions that preclude informed decision-making or compliance with the protocol treatment or follow-up

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Chunhee Choo, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Carlos Vargas, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20260182

Mayo Clinic Footer